TOWA PHARMACEUTICAL CO.,LTD. (4553.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

11.0x

EV/EBITDA

9.2x

Market Cap

JPY 179.68B

MomentumView details →

1D Return

+0.27%

YTD Return

−1.65%

RSI (14)

33.5

ValuationView details →

P/E (Fwd)

11.0x

EV/EBITDA

9.2x

Market Cap

JPY 179.68B

RSI (14)

33.5

MomentumView details →

1D Return

+0.27%

YTD Return

−1.65%

ProfitabilityView details →

Gross Margin

35.09%

Net Margin

7.94%

EBITDA Margin

14.42%

ROE (TTM)

11.30%

ROA (TTM)

4.39%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

+6.54%

EPS YoY

+11.22%

FCF YoY

+122.79%

Revenue CAGR 3Y

+16.16%

EPS CAGR 3Y

+6.05%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.02x

Current Ratio

2.83x

Quick Ratio

2.30x

Div Yield

2.19%

Div Rate

—

Div Growth 1Y

+16.67%

Financials snapshotView financials →

Revenue (TTM)

269.92B

Net Income (TTM)

21.44B

Op. CF (TTM)

30.83B

Next earningsNov 16, 2026 →

Latest newsMore news →

Towa Pharmaceutical announced it received additional regulatory approval for its lenalidomide capsules 2.5mg/5mg 'TOWA', expanding the indications to include relapsed or refractory follicular lymphoma and marginal zone lymphoma, along with corresponding dosage and administration.10d ago

Towa Pharmaceutical announced on August 17 that it obtained manufacturing and marketing approval for 18 generic drug products across 7 ingredients, including first-time approvals for 4 ingredients such as guanfacine extended-release tablets for ADHD and linagliptin tablets for type 2 diabetes.18d ago

Similar companies

SAWAI GROUP HOLDINGS Co.,Ltd.4887.T KISSEI PHARMACEUTICAL CO.,LTD.4547.T KAKEN PHARMACEUTICAL CO.,LTD.4521.T GNI Group Ltd.2160.T PeptiDream Inc.4587.T Nippon Shinyaku Co.,Ltd.4516.T Find similar companies →

Latest newsMore news →

Towa Pharmaceutical announced it received additional regulatory approval for its lenalidomide capsules 2.5mg/5mg 'TOWA', expanding the indications to include relapsed or refractory follicular lymphoma and marginal zone lymphoma, along with corresponding dosage and administration.10d ago Towa Pharmaceutical announced on August 17 that it obtained manufacturing and marketing approval for 18 generic drug products across 7 ingredients, including first-time approvals for 4 ingredients such as guanfacine extended-release tablets for ADHD and linagliptin tablets for type 2 diabetes.18d ago